Omid Farokhzad (file photo)
Seer raises $55M as proteomics approaches prime time in disease detection, drug development
Omid Farokhzad was working in his Harvard nanotech lab in 2017 when he found something he knew would become his next company. Two years and, as of today, over $100 million in funding for later, he still hasn’t revealed what it is.
“We’ve seen them reported, but we don’t really know what their technology is or what it does.” Stephen Williams, the CMO of SomaLogic, the most high-profile potential competitor to Farokhzad’s company, Seer, told Endpoints News.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
